Gilead Sciences, Inc. (LON: 0QYQ)

Market Cap	94.15B
Revenue (ttm)	21.11B
Net Income (ttm)	94.01M
Shares Out	n/a
EPS (ttm)	0.07
PE Ratio	1,001.48
Forward PE	n/a
Dividend	2.41 (2.63%)
Ex-Dividend Date	Dec 13, 2024

Volume	n/a
Average Volume	28,249
Open	n/a
Previous Close	92.41
Day's Range	n/a
52-Week Range	49.43 - 78.63
Beta	0.19
RSI	54.82
Earnings Date	Feb 3, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 18,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QYQ

Financial Performance

In 2023, Gilead Sciences's revenue was $27.12 billion, a decrease of -0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37%.

Financial numbers in USD